
Rhelion's Filament Health presents at FDA hearing on future therapeutic use of psychedelics.
Rhelion Life Sciences' subsidiary Filament Health Corp. participated in the FDA public hearing on September 14, 2026, discussing the potential future therapeutic use of psychedelic drugs. Filament's president, Sarit Hashkes, provided oral remarks hig...





